Bausch & Lomb, Novartis Ophthalmics to promote uveitis treatment

March 1, 2006

Bausch & Lomb and Novartis Ophthalmics will promote the fluocinolone acetonide intravitreal implant, 0.59 mg (Retisert) in the United States. Bausch & Lomb's patented orphan drug treats chronic noninfectious posterior segment uveitis.

Bausch & Lomb and Novartis Ophthalmics will promote the fluocinolone acetonide intravitreal implant, 0.59 mg (Retisert) in the United States. Bausch & Lomb's patented orphan drug treats chronic noninfectious posterior segment uveitis.

The Novartis retinal sales team will target its network of retinal specialists, in order to supplement the efforts of Bausch & Lomb's pharmaceutical sales representatives. Bausch & Lomb will continue its responsibilities of marketing and product strategy.